Among the top 10 core targets for SD treatment of DM, AKT1 (PDB ID: 7NH5), BCL2 (PDB ID: 5JSN), and STAT3 (PDB ID: 6TLC) with the highest degree values were selected for molecular docking with five potential active components: quercetin, taraxerol, spinasterol, isoquercitrin, and syringin (Table S6). This evidence concerns the gene AKT1 and diabetes mellitus.